Skip to main content

Table 1 Clinical and demographic data of ankylosing spondylitis patients at baseline

From: IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients

  Ankylosing spondylitis (n = 86)  
Variable Active-AS Control-AS p value
  (BASDAI ≥4; n = 47) (BASDAI <4; n = 39)  
Gender, male (%) 35 (74 %) 29 (74 %) 1.00
Age (years) 38.0 ± 11.1 49.5 ± 10.5 <0.001
Caucasian (%) 42 (89 %) 29 (74 %) 0.09
Peripheral involvement (%) 31 (66 %) 23 (59 %) 0.65
HLA-B27 positive (%) 82 % 90 % 0.36
Disease duration (years) 10.8 ± 4.5 17.6 ± 8.9 0.007
ASDAS-CRP 3.9 ± 1.0 2.0 ± 0.8 <0.001
BASFI 5.8 ± 2.3 3.8 ± 2.1 <0.001
BASMI 4.5 ± 2.7 5.8 ± 2.7 0.03
ASQoL 12.6 ± 4.8 5.3 ± 4.1 <0.001
CRP (mg/l) 29.7 ± 39.6 4.6 ± 3.5 <0.001
ESR (mm/hour) 29.7 ± 23.3 6.9 ± 6.6 <0.001
mSASSS 15.8 ± 18.9 37.9 ± 25.5 <0.001
NSAID intake score (0–100) 70.3 ± 44.8 68.3 ± 41.4 0.77
Methotrexate (%) 23 (48 %) 2 (0.5 %) <0.001
Sulphasalazine (%) 27 (57 %) 21 (53 %) 0.83
Leflunomide (%) 2 (4.2 %) 1 (0.02 %) 1.00
  1. All values are expressed as the mean ± standard deviation, except proportions (%)
  2. Nonparametric tests were performed for data that failed the normal distribution
  3. AS ankylosing spondylitis, ASDAS-CRP Ankylosing Spondylitis Disease Activity Score-C-reactive protein, ASQoL Ankylosing Spondylitis Quality of Life, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath AS Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, NSAID nonsteroidal anti-inflammatory drug